AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29605187 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotics
Number of subjects: 75
Study 29121294 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine i.v. infusion (25 μg h ‐1 for 24 h)
Number of subjects: 64
Study 29121294 — intervention group
Group type: COMPARATOR
Intervention: Morphine (equianalgesic dose)
Number of subjects: 64
Study 25637938 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine, 0.25% 30 mL
Number of subjects: 89
Study 25637938 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine, 0.25% 30 mL with 1‐mg dexamethasone
Number of subjects: 89
Study 25637938 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine, 0.25% 30 mL with 2‐mg dexamethasone
Number of subjects: 89
Study 25637938 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine, 0.25% 30 mL with 4‐mg dexamethasone
Number of subjects: 89
Study 25637938 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone (all doses)
Number of subjects: 89
Study 23618502 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months neo-adjuvant androgen suppression (NAS) before radiotherapy (RT)
Number of subjects: 802
Study 23618502 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months neo-adjuvant androgen suppression (NAS) before radiotherapy (RT)
Number of subjects: 802
Study 23618502 — intervention group
Group type: COMPARATOR
Intervention: 0 months neo-adjuvant androgen suppression (NAS) before radiotherapy (RT)
Number of subjects: 802
Study 21413116 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel coated balloon + endothelial progenitor capture stent
Number of subjects: 0
Study 21413116 — intervention group
Group type: COMPARATOR
Intervention: Drug eluting stent (DES)
Number of subjects: 0
Study 21413116 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial progenitor capture stent
Number of subjects: 0
Study 18296973 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 64
Study 18296973 — intervention group
Group type: EXPERIMENTAL
Intervention: Tennis-specific Drills Training (TDT)
Number of subjects: 64
Study 18296973 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (CT)
Number of subjects: 64
Study 18296973 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 64
Study 16458131 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstream use of small molecule GP IIb/IIIa inhibitors for all ACS patients
Number of subjects: 0
Study 16458131 — intervention group
Group type: COMPARATOR
Intervention: Selective use of abciximab only in patients requiring PCI
Number of subjects: 0
Study 12758236 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus mitomycin C (MMC) (15 mg/m² single injection at the end of the first week of radiotherapy)
Number of subjects: 478
Study 12758236 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 478
Study 12758236 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus mitomycin C (MMC)
Number of subjects: 478
Study 10739392 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg aspirin/day p.o. for 11 days
Number of subjects: 10
Study 10739392 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin/day p.o. for 11 days
Number of subjects: 10
Study 10739392 — intervention group
Group type: COMPARATOR
Intervention: 100 mg L-aspirin infusion
Number of subjects: 10
Study 10739392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of aspirin
Number of subjects: 10
Study 9214283 — intervention group
Group type: EXPERIMENTAL
Intervention: bifacid
Number of subjects: 60
Study 9214283 — intervention group
Group type: COMPARATOR
Intervention: bifidumbacterin
Number of subjects: 60
Study 8157945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg for the first month, 20 mg for the second month, 40 mg for the remaining 4 months)
Number of subjects: 50
Study 8157945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3063660 — intervention group
Group type: EXPERIMENTAL
Intervention: Penfluridol, administered once weekly
Number of subjects: 0
Study 3063660 — intervention group
Group type: COMPARATOR
Intervention: Trifluoperazine, administered twice daily
Number of subjects: 0
Study 29624540 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Steady State Response (ASSR)
Number of subjects: 102
Study 29624540 — intervention group
Group type: COMPARATOR
Intervention: Auditory Brainstem Response (ABR)
Number of subjects: 102
Study 28120856 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine supplementation (2 g per day)
Number of subjects: 56
Study 28120856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 56
Study 24589310 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose MDCT
Number of subjects: 1000
Study 24589310 — intervention group
Group type: COMPARATOR
Intervention: Ultra-low dose MDCT
Number of subjects: 1000
Study 22592040 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive compressive stockings (10 mm Hg at ankle, 23 mm Hg at upper calf)
Number of subjects: 401
Study 22592040 — intervention group
Group type: COMPARATOR
Intervention: Degressive compressive stockings (30 mm Hg at ankle, 21 mm Hg at upper calf)
Number of subjects: 401
Study 22592040 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive compressive stockings
Number of subjects: 401
Study 22592040 — intervention group
Group type: COMPARATOR
Intervention: Degressive compressive stockings
Number of subjects: 401
Study 22592040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 401
Study 20211294 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily (2.5 mg twice daily in selected patients)
Number of subjects: 5600
Study 20211294 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 81 to 324 mg once daily
Number of subjects: 5600
Study 17966532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg)
Number of subjects: 40
Study 17966532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 15298986 — intervention group
Group type: EXPERIMENTAL
Intervention: ULLS plus Resistance Exercise (RE)
Number of subjects: 31
Study 15298986 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) only
Number of subjects: 31
Study 15298986 — intervention group
Group type: COMPARATOR
Intervention: Unilateral Limb Suspension (ULLS)
Number of subjects: 31
Study 11850750 — intervention group
Group type: EXPERIMENTAL
Intervention: AGB plus surgical removal of the total greater omentum
Number of subjects: 50
Study 11850750 — intervention group
Group type: COMPARATOR
Intervention: AGB alone
Number of subjects: 50
Study 9659857 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/day of olanzapine
Number of subjects: 84
Study 9659857 — intervention group
Group type: COMPARATOR
Intervention: 1200 mg/day of chlorpromazine plus 4 mg/day of benztropine mesylate
Number of subjects: 84
Study 7982430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 86
Study 7982430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 2500466 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended treatment of 40 weekly sessions
Number of subjects: 48
Study 2500466 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of 20 weekly sessions
Number of subjects: 48
Study 31745855 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT (combined cCBT-only and cCBT+ISG groups)
Number of subjects: 689
Study 31745855 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT
Number of subjects: 689
Study 31745855 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 689
Study 31226526 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid/tetracycline gel (CAT) group
Number of subjects: 17
Study 31226526 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT group
Number of subjects: 17
Study 31226526 — intervention group
Group type: COMPARATOR
Intervention: Control group (SRP)
Number of subjects: 17
Study 28963921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural competence education delivered via Facebook (FB)
Number of subjects: 180
Study 28963921 — intervention group
Group type: COMPARATOR
Intervention: Regular educational program (Control Group)
Number of subjects: 180
Study 25684586 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg orally once daily
Number of subjects: 1945
Study 25684586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1945
Study 23343391 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening with information and home sampling
Number of subjects: 10000
Study 23343391 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 10000
Study 21700430 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 10-16 mg
Number of subjects: 3580
Study 21700430 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 20-24 mg
Number of subjects: 3580
Study 21700430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3580
Study 18339212 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (6% hydroxyethyl starch, Voluven)
Number of subjects: 81
Study 18339212 — intervention group
Group type: COMPARATOR
Intervention: Human albumin 5%
Number of subjects: 81
Study 16701187 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL bupivacaine plus midazolam 2 mg
Number of subjects: 60
Study 16701187 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL bupivacaine plus midazolam 1 mg
Number of subjects: 60
Study 16701187 — intervention group
Group type: COMPARATOR
Intervention: 2 mL hyperbaric bupivacaine 0.5%
Number of subjects: 60
Study 12921806 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise regional circulatory occlusion (PE-RCO) during arm exercises
Number of subjects: 12
Study 12921806 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise regional circulatory occlusion (PE-RCO) during leg exercises
Number of subjects: 12
Study 12921806 — intervention group
Group type: COMPARATOR
Intervention: Passive movement mechanoreflex
Number of subjects: 12
Study 12921806 — intervention group
Group type: COMPARATOR
Intervention: Active exercise mechanoreflex
Number of subjects: 12
Study 12921806 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaboreflex reproducibility in heart failure patients
Number of subjects: 12
Study 12921806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanoreflex reproducibility during passive movement
Number of subjects: 12
Study 12921806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanoreflex reproducibility during active exercise
Number of subjects: 12
Study 11092646 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg (combined with medroxyprogesterone acetate 2.5 mg daily in five women with uterus intact)
Number of subjects: 10
Study 9126089 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 34
Study 9126089 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg paroxetine
Number of subjects: 34
Study 9126089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in the 20 mg group)
Number of subjects: 34
Study 1530172 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of lidocaine + 0.05 mg of fentanyl + 0.5 mg of pancuronium (group D)
Number of subjects: 80
Study 1530172 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of lidocaine + 0.05 mg of fentanyl (group B)
Number of subjects: 80
Study 1530172 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of lidocaine + 0.5 mg of pancuronium (group C)
Number of subjects: 80
Study 1530172 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of lidocaine (group A)
Number of subjects: 80
Study 1530172 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of lidocaine + 0.05 mg of fentanyl + 0.5 mg of pancuronium (group E) for safety evaluation
Number of subjects: 80
Study 3924285 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 19
Study 3924285 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 19
Study 31689326 — intervention group
Group type: EXPERIMENTAL
Intervention: Organised mass prostate-cancer screening based on PSA testing
Number of subjects: 80149
Study 31689326 — intervention group
Group type: COMPARATOR
Intervention: Control group (no organised screening)
Number of subjects: 80149
Study 27627098 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-α treatments
Number of subjects: 0
Study 27627098 — intervention group
Group type: COMPARATOR
Intervention: Non-responder patients
Number of subjects: 0
Study 27627098 — intervention group
Group type: EXPERIMENTAL
Intervention: CRABP-II SNPs analysis
Number of subjects: 0
Study 27160164 — intervention group
Group type: COMPARATOR
Intervention: Exercise intervention (twice a week for 12 months)
Number of subjects: 194
Study 24237879 — intervention group
Group type: COMPARATOR
Intervention: Intranasal midazolam (0.2 mg·kg(‐1))
Number of subjects: 72
Study 24237879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (1 μg·kg(‐1))
Number of subjects: 72
Study 24237879 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 22119927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavac(®) vaccine manufactured at large scale
Number of subjects: 720
Study 22119927 — intervention group
Group type: COMPARATOR
Intervention: Pentavac(®) vaccine manufactured at small scale
Number of subjects: 720
Study 20580361 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) 20 mg vaginally
Number of subjects: 48
Study 20580361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19205545 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg daily
Number of subjects: 22
Study 19205545 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment plus placebo
Number of subjects: 22
Study 16910456 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical cotton swab
Number of subjects: 100
Study 16910456 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral cotton swab
Number of subjects: 100
Study 16910456 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon shape cotton swab
Number of subjects: 100
Study 16910456 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyto‐brush
Number of subjects: 100
Study 11772176 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rakosi Functional Analysis
Number of subjects: 30
Study 10352617 — intervention group
Group type: EXPERIMENTAL
Intervention: NC100150 injection with respiratory gating
Number of subjects: 9
Study 9082765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal immunization with P6 (twice, with 2 weeks in between)
Number of subjects: 24
Study 9082765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of rIL-2 and rIL-5
Number of subjects: 24
Study 1937985 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil (50 mg thrice daily)
Number of subjects: 12
Study 1937985 — intervention group
Group type: COMPARATOR
Intervention: diltiazem (60 mg thrice daily)
Number of subjects: 12
Study 6128086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol (PB) 20 mg three times daily
Number of subjects: 12
Study 6128086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6128086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol (PB) 20 mg and 30 mg doses
Number of subjects: 12
Study 30950094 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Cigarettes
Number of subjects: 0
Study 28844499 — intervention group
Group type: EXPERIMENTAL
Intervention: Rindopepimut (500 μg admixed with 150 μg GM‐CSF) plus standard oral temozolomide (150–200 mg/m2 for 5 of 28 days) for 6–12 cycles or longer.
Number of subjects: 745
Study 28844499 — intervention group
Group type: COMPARATOR
Intervention: Control (100 μg keyhole limpet haemocyanin) plus standard oral temozolomide (150–200 mg/m2 for 5 of 28 days) for 6–12 cycles or longer.
Number of subjects: 745
Study 28844499 — intervention group
Group type: EXPERIMENTAL
Intervention: Rindopepimut group
Number of subjects: 745
Study 28844499 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 745
Study 24615546 — intervention group
Group type: EXPERIMENTAL
Intervention: CMCA (community environmental change intervention)
Number of subjects: 0
Study 24615546 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNECT (population-wide intervention based on SBIRT)
Number of subjects: 0
Study 23957500 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel image analysis tool for TEM
Number of subjects: 0
Study 23957500 — intervention group
Group type: COMPARATOR
Intervention: Traditional diagnostic approaches without the novel tool
Number of subjects: 0
Study 21406671 — intervention group
Group type: EXPERIMENTAL
Intervention: SUSTAIN intervention (chronic care model-based program including group clinics, self-management support, report cards, decision support through care guides and protocols, and coordination of ongoing care)
Number of subjects: 268
Study 21406671 — intervention group
Group type: EXPERIMENTAL
Intervention: SUSTAIN intervention
Number of subjects: 268
Study 19269731 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate (CAVITY CLEANSER) applied for 60s on acid etched dentine
Number of subjects: 3
Study 19269731 — intervention group
Group type: COMPARATOR
Intervention: No chlorhexidine treatment (Control)
Number of subjects: 3
Study 17381964 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 3.9 g/d
Number of subjects: 62
Study 17381964 — intervention group
Group type: COMPARATOR
Intervention: High-oleic acid sunflower oil
Number of subjects: 62
Study 15200656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 1 mg x kg(‐1) (max 25 mg)
Number of subjects: 45
Study 15200656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11396396 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 97
Study 11396396 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 97
Study 11396396 — intervention group
Group type: COMPARATOR
Intervention: Control (fellow unoperated eyes)
Number of subjects: 97
Study 9413764 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc content in benign prostatic hyperplasia (BPH)
Number of subjects: 109
Study 9413764 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc content in cancer
Number of subjects: 109
Study 9413764 — intervention group
Group type: COMPARATOR
Intervention: Zinc content in normal prostate
Number of subjects: 109
Study 9413764 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc assessment in transrectal puncture biopsy
Number of subjects: 109
Study 8387191 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (2 x 400 micrograms/d by spacer)
Number of subjects: 15
Study 8387191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil (4 x 4 mg/d)
Number of subjects: 15
Study 8387191 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 15
Study 8387191 — intervention group
Group type: COMPARATOR
Intervention: Nedocromil
Number of subjects: 15
Study 3440107 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectally administered carbamazepine mixture
Number of subjects: 0
Study 3440107 — intervention group
Group type: COMPARATOR
Intervention: Orally administered carbamazepine mixture
Number of subjects: 0
Study 31888762 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg omega-3 fatty acid twice a day + vitamin D placebo every two weeks
Number of subjects: 168
Study 31888762 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid placebo twice a day + 50,000 IU vitamin D every two weeks
Number of subjects: 168
Study 31888762 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg omega-3 fatty acid twice a day + 50,000 IU vitamin D every two weeks
Number of subjects: 168
Study 31888762 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 fatty acid placebo twice a day + vitamin D placebo every two weeks
Number of subjects: 168
Study 28899842 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompting intervention
Number of subjects: 0
Study 27156748 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 151
Study 27156748 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 151
Study 27156748 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture
Number of subjects: 151
Study 24862674 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic(®) FOCUS
Number of subjects: 82
Study 24862674 — intervention group
Group type: COMPARATOR
Intervention: Traditional suture ligation (knot and tie)
Number of subjects: 82
Study 22421498 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tutorial
Number of subjects: 347
Study 22421498 — intervention group
Group type: COMPARATOR
Intervention: No tutorial
Number of subjects: 347
Study 20072045 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB + KIC (3 g.d HMB and 0.3 g.d KIC)
Number of subjects: 14
Study 20072045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g.d corn flour)
Number of subjects: 14
Study 17492341 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly absorbable polypropylene-polyglactin mesh (Vypro II(R) 50 g/m(2), 79 hernias)
Number of subjects: 228
Study 17492341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight polypropylene mesh (Premilene Mesh LP(R) 55 g/m(2), 75 hernias)
Number of subjects: 228
Study 17492341 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional densely woven polypropylene mesh (Premilene(R) 82 g/m(2), 78 hernias)
Number of subjects: 228
Study 17492341 — intervention group
Group type: COMPARATOR
Intervention: All meshes (Vypro, Premilene LP, Premilene)
Number of subjects: 228
Study 15630054 — intervention group
Group type: EXPERIMENTAL
Intervention: Full 6‐year intervention (grades 1 through 6)
Number of subjects: 605
Study 15630054 — intervention group
Group type: EXPERIMENTAL
Intervention: Late 2‐year intervention (grades 5 and 6 only)
Number of subjects: 605
Study 15630054 — intervention group
Group type: COMPARATOR
Intervention: No‐treatment control condition
Number of subjects: 605
Study 11852171 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory agents
Number of subjects: 0
Study 11852171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0